A recent study has claimed that a class of Type 2 diabetes medication is safer than its counterparts, but doctors remain cautious in prescribing it.
The study by biopharmaceutical company AstraZeneca found that patients with Type 2 diabetes taking sodium-glucose cotransporter-2 (SGLT2) inhibitors were less likely to be hospitalised for heart failure and suffer a heart attack or stroke, when compared with patients taking other medication for the same type of disease.
TO READ THE FULL ARTICLE
Thank you for reading The Straits Times
You have reached one of our Premium stories. To continue reading, get access now or log in if you are a subscriber.
What is Premium?